Avecho Biotechnology (ASX:AVE) Total Liabilities: A$5.55 Mil (As of Dec. 2025)


What is Avecho Biotechnology Total Liabilities?

Avecho Biotechnology ASX:AVE Total Liabilities is A$5.55 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Avecho Biotechnology's Total Liabilities for the quarter that ended in Dec. 2025 was A$5.55 Mil.

Avecho Biotechnology's quarterly Total Liabilities increased from Dec. 2024 (A$1.73 Mil) to Jun. 2025 (A$6.37 Mil) but then declined from Jun. 2025 (A$6.37 Mil) to Dec. 2025 (A$5.55 Mil).

Avecho Biotechnology's annual Total Liabilities increased from Dec. 2023 (A$0.94 Mil) to Dec. 2024 (A$1.73 Mil) and increased from Dec. 2024 (A$1.73 Mil) to Dec. 2025 (A$5.55 Mil).

Avecho Biotechnology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Avecho Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avecho Biotechnology Total Liabilities Chart

Avecho Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.92 0.94 1.73 5.55

Avecho Biotechnology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 1.65 1.73 6.37 5.55

Avecho Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avecho Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.709+(0+4.837
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.55

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=7.106-1.56
=5.55

Avecho Biotechnology's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.709+(0+4.837
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.55

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=7.106-1.56
=5.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$5.55 Mil mean?
Avecho Biotechnology (ASX:AVE) has a Total Liabilities of A$5.55 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Avecho Biotechnology and its competitors.
Is Avecho Biotechnology's Total Liabilities too high?
Avecho Biotechnology's current Total Liabilities is A$5.55 Mil.
How does Avecho Biotechnology's Total Liabilities compare to VRTX and REGN?
Avecho Biotechnology's Total Liabilities of A$5.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Avecho Biotechnology and its competitors. Avecho Biotechnology's current Total Liabilities is A$5.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Total Liabilities of A$5.55 Mil. The current Total Liabilities is A$5.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Total Liabilities is A$5.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avecho Biotechnology Business Description

Other Exchanges OEZ:Germany
Address Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.